Shandong Boan Biotechnology Co., Ltd.
山东博安生物技术股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6955)

VOLUNTARY ANNOUNCEMENT

BLA SUBMISSION FOR AFLIBERCEPT INTRAVITREOUS INJECTION IN BRAZIL

The board of directors (the "**Board**") of Shandong Boan Biotechnology Co., Ltd. (the "**Company**") announces that the Company has submitted a Biologics License Application ("**BLA**") to the Brazilian Health Regulatory Agency (ANVISA) for the Company's Aflibercept Intravitreous Injection ("**BA9101**"), intended for the treatment of neovascular (wet) age-related macular degeneration ("**nAMD**") and diabetic macular edema ("**DME**") in adults.

BA9101, a biosimilar to EYLEA®, was approved for marketing in China in November 2025 and is marketed under the trade name Boyoujing®. As one of the Company's key products under its global strategy, BA9101 is being developed across international markets. In June 2025, the Company partnered with Kexing Risedo Pharm Co., Ltd., a wholly-owned subsidiary of Kexing Biopharm, granting the latter the exclusive rights to commercialize BA9101 globally (excluding the Chinese mainland, the EU, the UK, the U.S., and Japan). Currently, regulatory submissions and commercial launches are progressing on schedule across targeted territories.

Globally, EYLEA® has been approved for various ophthalmic indications, including nAMD, DME, macular edema following retinal vein occlusion (RVO), diabetic retinopathy (DR), visual impairment due to myopic choroidal neovascularization (mCNV), and retinopathy of prematurity (ROP). Retinal diseases like nAMD and DME are the leading causes of vision impairment and blindness worldwide. With increasing screen time and an aging population, the prevalence of these conditions is expected to continue rising.

Aflibercept, the active ingredient of EYLEA®, is a humanized fusion protein that binds with vascular endothelial growth factors (VEGF-A and VEGF-B) and placental growth factor (PlGF) to reach more targets than anti-VEGF monoclonal antibodies. As a first-line treatment for nAMD, DME, and other retinal diseases, aflibercept sustainably inhibits intraocular VEGFs to effectively improve visual acuity with durable efficacy and a favorable overall safety and tolerability profile.

The development of BA9101 adhered to regulatory guidelines for biosimilars across China, the U.S., and the EU. Its similarity to EYLEA® was established through a series of analytical, non-clinical, and clinical studies. The two products were shown to be highly similar in quality, efficacy, safety, and immunogenicity, with no clinically meaningful differences.

Furthermore, the manufacturing and quality control of BA9101 adhere to international standards. The Company's manufacturing facility was designed and built to state-of-the-art specifications, and the production processes are continuously refined and upgraded. The Company has established a quality management system that complies with Chinese, the U.S. and EU standards, ensuring the quality of BA9101 and future products for overseas markets.

Substantial unmet medical needs and robust clinical efficacy underpin the commercial potential of BA9101. The pharmaceutical market in Brazil reached US$39 billion in 2024, and is projected to grow at a compound annual growth rate (CAGR) of 9% from 2025 to 2029. At the same time, the reference product EYLEA® achieved global sales of US$5.321 billion in 2025.

The Company believes that Brazil, as one of the world's top ten pharmaceutical markets and the largest in Latin America, serves as a strategic hub for expanding into emerging markets. The BLA submission in Brazil represents an important step in bringing BA9101 to patients worldwide. Moving forward, the Company will work closely with leading partners to advance the registration and commercialization of BA9101 in other countries, enhancing patient access to premium Chinese biologics for individuals with retinal diseases while establishing a new growth driver for the Company.

By Order of the Board
Shandong Boan Biotechnology Co., Ltd.
Jiang Hua
Chairlady, Chief Executive Officer and Executive Director

Yantai, the People's Republic of China, 5 August 2026

As at the date of this announcement, the executive directors of the Company are Ms. Jiang Hua and Mr. Wang Shenghan; the non-executive directors of the Company are Mr. Liu Yuanchong, Ms. Li Li and Mr. Li Shixu; and the independent non-executive directors of the Company are Professor Shi Luwen, Mr. Dai Jixiong and Dr. Yu Jialin.